<DOC>
	<DOCNO>NCT00716365</DOCNO>
	<brief_summary>USF Hemostasis - USage HemCon Femoral Hemostasis Percutaneous Procedures . A Comparative Open Label Study The purpose trial test HemCon pad diagnostic percutaneous coronary angiography adjunct manual compression well control vascular access site bleed reduce time-to-hemostasis . We hypothesize use HemCon bandage ( contain carbohydrate call chitosan , find shell shrimp , lobster beetle ) shorten time need achieve hemostasis , time patient 's ambulation , patient 's satisfaction without increase vascular complication . 278 patient undergoing diagnostic coronary angiography receive 2500 u intravenous Heparin study randomize manual homeostasis either HemCon regular pad . Primary efficacy endpoint time hemostasis . Secondary endpoint safety ( complication rate ) satisfaction patient regard time sit incline time ambulation . 25 % patient arm randomize Duplex examination femoral artery access site .</brief_summary>
	<brief_title>USF Hemostasis : USage HemCon Femoral Hemostasis After Percutaneous Procedures</brief_title>
	<detailed_description>USF Hemostasis USage HemCon Femoral Hemostasis Percutaneous Procedures A Comparative Open Label Study Introduction After completion angiography perform via femoral artery , hemostasis achieve apply local pressure either manually mechanical device 10-20 minute . This time consume physician , uncomfortable patient occasionally complicate vascular event increase morbidity hospital duration reduce patient satisfaction . Closure device develop shorten pressure time costly . The HemCon pad compose bandage contain carbohydrate call chitosan , find shell shrimp , lobster beetle . Its molecule positively charge attract negatively charge blood cell platelet , thus promote clotting . Chitosan hemorrhage control dress show effective animal model severe hemorrhage ( 1-4 ) . Bandage . U.S. military personnel Iraquean Afghanistan conflict use HemCon Bandage successfully stop arterial hemorrhage control conventional bandage 64 patient without adverse effect ( 3,5 ) . The HemCon bandage also FDA-cleared hemostatic dressing suitable use hemodialysis access puncture ( 2 ) . The purpose trial test HemCon pad diagnostic percutaneous coronary angiography adjunct manual compression well control vascular access site bleed reduce time-to-hemostasis . We hypothesize use HemCon bandage shorten time need achieve hemostasis , time patient 's ambulation , patient 's satisfaction without increase vascular complication . Endpoints Primary endpoint - Compare efficacy ( time hemostasis ) HemCon regular pad Secondary endpoint - Compare efficacy ( time ambulation ) HemCon regular pad - Compare safety ( complication rate ) HemCon regular pad use protocol short time ambulation HemCon pad . - Compare satisfaction patient regard time sit incline time ambulation . Patients 278 patient undergoing diagnostic coronary angiography receive 2500 u intravenous Heparin study randomize write hereinafter . Inclusion Criteria : - Age 18-80 year old - Signing informed consent - Percutaneous coronary angiography 6 french sheath via femoral artery - Post catheterization non-invasive systolic blood pressure 150 mm Hg Exclusion criterion : - STEMI - Patients receive IIb-IIIa antagonist angiography . - Patients receive 2500u IV Heparin 0.5 mg/kg LMWH within 8 hour procedure . - Known bleeding tendency , disturb clot system platelet function - Evidence bleeding hematoma access site prior sheath removal . Protocol Heparin treatment : All patient receive IV 2500 u Heparin immediately introduce femoral sheath . - Procedure duration : Procedure duration record minute . - Randomization : A 1:1 randomization HemCon regular pad perform completion procedure . Envelopes mark consecutive number contain note write : `` HemCon pad '' `` Regular pad `` . Notes content randomize computer program . After procedure complete decision take withdraw sheath next consecutive envelope open determine sheath removal technique use . - Arterial sheath removal : 1 . The femoral sheath remove patient 's bed ( angiography table ) . One ml blood allow flow access site . A HemCon regular pad ( accord randomization ) apply manually occlusive pressure 5 minute . 2 . After 5 minute operator release pressure . If bleeding continue , application local pressure resume . After stage , operator allow release pressure every 5 minute longer operator 's discretion . The total number pressure release total time hemostasis record . 3 . After achieve hemostasis pressure bandage apply access site 3 hour . Bed rest : 1 . Minimal bed rest duration 2 hour . Longer bed rest duration increment 30 minute decide operator 's discretion accord hemostasis . Total bed rest time record . 2 . During bed rest operator may allow patient sit 450 incline 1 hour . Time sit record . 3 . If hematoma occurs , evaluate palpation diameter measurement record . - Ambulation : After bed rest , ambulation allow provide confound event blood pressure abnormalities hematoma develop . - In hospital follow-up : 1 . A duplex examination femoral artery access site perform operator 's discretion . 2 . One day procedure patient 's complaint physical finding record . 3 . Blood count take patient day procedure . Earlier blood count blood examination may take operator 's discretion record . - Discharge : The patient discharge operator 's discretion . Complications adverse event note record upon discharge . â€¢ Out hospital patient 's satisfaction follow : One day discharge patient contact phone ask procedural complication ( groin pain , hematoma ) appear discharge . If need , patient invite hospital investigation . During phone call patient ask / satisfaction ambulation procedure scale 1-10 ( 10 mostly satisfactory ) . Statistics The follow data compare 2 group use t-test : - Time hemostasis - Duration bed rest ( total , supine position incline sit-up position ) - Incidence minor major hematoma - Hematoma size - Post procedural stay hospital - Level satisfaction evidence post-procedure satisfaction survey . The number patient study ( 278 ) calculate assumption HemCon achieve decrease 30 % hemostasis time ( primary endpoint ) , alpha value 0.05 power 0.8 . REFERENCES 1 . Pausateri AE , McCarthy SG , et al . Effect chitosan-based hemostatic dress blood loss survival model severe venous hemorrhage hepatic injury swine . J Trauma . 2003 ; 54:177-182 . 2 . Gustafson SB , Fulkerson P , et al . Chitosan dress provide hemostasis swine femoral arterial injury model . Prehospital emergency care . 2007 ; 11 : 172-178 . 3 . Wedmore I , McManus JG , et al . A special report chitosan base hemostatic dressing : Experience current combat operation . J Trauma . 2006 ; 60:655- 658 .</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Age 1880 year old Signing inform consent Percutaneous coronary angiography 6 french sheath via femoral artery Post catheterization noninvasive systolic blood pressure 150 mm Hg Exclusion criterion : STEMI Patients receive IIbIIIa antagonist angiography . Patients receive 2500u IV Heparin 0.5 mg/kg LMWH within 8 hour procedure . Known bleeding tendency , disturb clot system platelet function Evidence bleeding hematoma access site prior sheath removal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>angiography</keyword>
	<keyword>hemostasis</keyword>
	<keyword>femoral artery</keyword>
	<keyword>duplex</keyword>
</DOC>